Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emerging Companies

EISAI

Eisai to share clinical trial data via external website

Company aims to further promote transparency in the industry

- PMLiVE

Afinitor set for filing this year in neuroendocrine cancer

Novartis drug is already approved for breast and renal cancers

- PMLiVE

Ipsen acquires OctreoPharm to boost its oncology presence

Will aid the development of its approach to neuroendrocrine tumours

- PMLiVE

Novartis still hungry after absorbing GSK oncology

CEO says firm is looking to strengthen pipelines in its three businesses

Roche Basel Switzerland

Roche adds kidney cancer to anti-PD-L1 programme

Inhibitor already indicated for lung, bladder and breast cancer

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

EISAI

Eisai to make 200 cuts to US operations

Japanese firm says the restructure will help it stay competitive

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

- PMLiVE

GSK and Lilly invest in $100m global Dementia Discovery Fund

Fund announced at WHO conference by UK health secretary Jeremy Hunt

UK flag

Cancer Drugs Fund a ‘missed opportunity’, says MP

Chair of the Liberal Democrat health committee Paul Burstow says the CDF should have gone further

- PMLiVE

Merck and Eisai link up on anti-PD-1 combinations

Will test Keytruda with both Lenvima and Halaven 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links